Immunotherapy has established a new paradigm for
cancer treatment and made many breakthroughs in clinical practice. However, the rarity of immune response suggests that additional intervention is necessary. In recent years, it has been reported that local
tumor destruction (LTD) can cause
cancer cell death and induce an immunologic response. Thus, the combination of
immunotherapy and LTD methods will be a promising approach to improve immune efficiency for
cancer treatment. Herein, a nanobiotechnology platform to achieve high-precision LTD for systemic
cancer immunotherapy has been successfully constructed. Possessing radio-sensitizing and photothermal properties, the engineered
immunoadjuvant-loaded nanoplatform, which could precisely induce
radiotherapy (RT)/
photothermal therapy (PTT) to eliminate local
tumor and meanwhile lead to the release of
tumor-derived
protein antigens (TDPAs), has been facilely fabricated by commercialized SPG membrane emulsification technology. Further on, the TDPAs could be captured and form personal
nanovaccines in situ to serve as both reservoirs of
antigen and carriers of
immunoadjuvant, which can effectively improve the immune response. The investigations suggest that the combination of RT/PTT and improved
immunotherapy using adjuvant-encapsulated
antigen-capturing nanoparticles holds tremendous promise in
cancer treatments.